A Phase I, Multicenter, Dose-Escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients With Advanced Solid Tumors Harboring FGFR Gene Alterations
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-1959
Full Text
Open PDFAbstract
Available in full text
Date
February 11, 2019
Authors
Publisher
American Association for Cancer Research (AACR)